Optimization of storage conditions for Puumala virus based vaccine

封面

如何引用文章

全文:

详细

We report the effects of storage conditions and human serum albumin addition to the vaccine composition on the immunogenic properties of an experimental vaccine against hemorrhagic fever with renal syndrome. To obtain an experimental vaccine, the Puumala virus, propagated in Vero cells culture, was concentrated, inactivated with beta-propiolactone, and purified by chromatography on the Capto™Core 700 multimodal sorbent (GE Healthcare). The target component in the vaccine was 2±0.2 × 106 of viral RNA copies/ml. The humoral immune response to the vaccine was determined by measuring the neutralizing antibodies in the blood serum of immunized Syrian hamsters (Mesocricetus auratus). It was revealed that the Puumala virus inactivated with beta-propiolactone induces a pronounced humoral immune response, which indicates preservation of relevant immunogenic epitopes. Аccording to our study, viral RNA is more stable during storage of the inactivated vs. intact virus. It was confirmed that full virus inactivation occurred after 24 hours of storage at 37°C. A significant decrease in the virus immunogenicity during the thermal inactivation was noted, which confirms the need for careful selection of storage conditions for thermolabile Hantaviruses. A direct correlation was observed between viral titer and viral RNA copy number/ml. Adding human serum albumin stabilized viral infectivity during storage: Puumala virus titer remained at the same level for 3 months of storage at 6±2°C, whereas without albumin, the titer decreased to undetectable level. The addition of 0.1% human serum albumin to the inactivated virus stabilized its immunogenic properties during long-term storage. It was shown that vaccine preparations with human serum albumin (0.1–1%) show higher dose-dependent stability upon repeated freezing assessed by detecting viral RNA level and their immunogenicity. It can be assumed that human serum albumin provides better preservation of of viral genetic material during storage, as well the protein epitopes responsible for the protective immune response in the form of neutralizing antibodies induction, undergo less pronounced conformational changes in the presence of albumin. These data support the addition of human serum albumin to the vaccine formulation.

作者简介

Anna Vetrova

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences; Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: ann.vetr.99@mail.ru

Research Laboratory Assistant, Laboratory of Hemorrhagic Fevers; Magistracy Student of Biotechnology

俄罗斯联邦, Moscow; Moscow

Svetlana Kurashova

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

PhD (Medicine), Leading Researcher, Laboratory of Hemorrhagic Fevers

俄罗斯联邦, Moscow

Rostislav Teodorovich

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

Researcher, Laboratory of Hemorrhagic Fevers

俄罗斯联邦, Moscow

Yulia Popova

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

Researcher, Laboratory of Hemorrhagic Fevers

俄罗斯联邦, Moscow

Ekaterina Blinova

Central Research Institute of Epidemiology of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance

Email: ann.vetr.99@mail.ru

Junior Researcher, Science Team for Genetic Engineering and Biotechnology

俄罗斯联邦, Moscow

Pavel Nabatnikov

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

Leading Technologist

俄罗斯联邦, Moscow

Evgeny Tkachenko

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

DSc (Medicine), Professor, Scientific Supervisor

俄罗斯联邦, Moscow

Tamara Dzagurova

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences

Email: ann.vetr.99@mail.ru

DSc (Medicine), Head of the Laboratory of Hemorrhagic Fevers

俄罗斯联邦, Moscow

参考

  1. Дзагурова Т.К., Ткаченко Е.А., Петров В.А. Эффективность применения культуральных антигенов для серодиагностики ГЛПС с помощью метода иммунофлюоресценции // Вопросы вирусологии. 1988. № 1. С. 71–75. [Dzagurova T.K., Tkachenko E.A., Petrov V.A. The effectiveness of culture antigens for HFRS serodiagnostics by means of the immunofluorescence method. Voprosy virusologii = Problems of Virology, 1988, no. 1, pp. 71–75. (In Russ.)]
  2. Егорова М.С., Курашова С.С., Дзагурова Т.К., Баловнева М.В., Ишмухаметов А.А., Ткаченко Е.А. Влияние инактивирующих вирус агентов на иммуногенность вакцин против геморрагической лихорадки с почечным синдромом // Биотехнология. 2020. Т. 36, № 2. С. 64–73. [Egorova M.S., Kurashova S.S., Dzagurova T.K., Balovneva M.V., Ishmukhametov A.A., Tkachenko E.A. The effect of virus inactivating agents on the immunogenicity of vaccines against hemorrhagic fever with renal syndrome. Biotekhnologiya = Biotechnology, 2020, vol. 36, no. 2, pp. 64–73. (In Russ.)] doi: 10.21519/0234-2758-2020-36-2-64-73
  3. Курашова С.С., Баловнева М.В., Ишмухаметов А.А., Теодорович Р.Д., Попова Ю.В., Ткаченко Е.А., Дзагурова Т.К. Гуморальный иммунный ответ после иммунизации морских свинок вакцинным препаратом на основе вируса Пуумала // Инфекция и иммунитет. 2022. Т. 12, № 5. C. 971–975. [Kurashova S.S., Balovneva M.V., Ishmukhametov A.A., Teodorovich R.D., Popova Yu.V., Tkachenko E.A., Dzagurova T.K. Immune response evaluation in the guinea pigs after immunization with the experimental Puumala virus vaccine. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, vol. 12, no. 5, pp. 971–975. (In Russ.)] doi: 10.15789/2220-7619-IRE-1956
  4. Ткаченко Е.А., Ишмухаметов А.А., Дзагурова Т.К., Синюгина А.А., Коротина Н.А., Набатников П.А., Соцкова С.Е., Баловнева М.В., Малкин А.Е. Разработка экспериментально-промышленной технологии производства вакцины для профилактики геморрагической лихорадки с почечным синдромом // Ремедиум. 2015. Т. 6. С. 47–53. [Tkachenko E.A., Ishmukhametov A.A., Dzagurova T.K., Sinyugina A.A., Korotina N.A., Nabatnikov P.A., Sotskova S.E., Balovneva M.V., Malkin A.E. Development of experimental and industrial technology for the production of a vaccine for the prevention of hemorrhagic fever with renal syndrome. Remedium = Remedium, 2015, vol. 6, pp. 47–53. (In Russ.)]
  5. Choo J.J.Y., McMillan C.L.D., Fernando G.J.P., Hall R.A., Young P.R., Hobson-Peters J., Muller D.A. Developing a stabilizing formulation of a live chimeric dengue virus vaccine dry coated on a high-density microarray patch. Vaccines (Basel), 2021, vol. 9, no. 11: 1301. doi: 10.3390/vaccines9111301
  6. Dzagurova T.K., Klempa B., Tkachenko E.A., Slyusareva G.P., Morozov V.G., Auste B., Kruger D.H. Molecular diagnostics of hemorrhagic fever with renal syndrome during a Dobrava virus infection outbreak in the European part of Russia. J. Clin. Microbiol., 2009, vol. 47, no. 12, pp. 4029–4036. doi: 10.1128/JCM.01225-09
  7. Egorova M.S., Kurashova S.S., Ishmukhametov A.A., Balovneva M.V., Deviatkin A.A., Safonova M.V., Ozherelkov S.V., Khapchaev Y.K., Balkina A.S., Belyakova A.V., Dzagurova T.K., Tkachenko E.A. [Real-time PCR assay development for the control of vaccine against hemorrhagic fever with renal syndrome]. Vopr. Virusol., 2021, vol. 66, no. 1, pp. 65–73. (In Russ.). doi: 10.36233/0507-4088-30
  8. Marth E., Kleinhappl B. Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine, 2001, vol. 20, no. 3–4, pp. 532–537. doi: 10.1016/s0264-410x(01)00329-2
  9. Miao J., Chard L.S., Wang Z., Wang Y. Syrian hamster as an animal model for the study on infectious diseases. Front. Immunol., 2019, vol. 10: 2329. doi: 10.3389/fimmu.2019.02329
  10. Safronetz D., Ebihara H., Feldmann H., Hooper J.W. The Syrian hamster model of hantavirus pulmonary syndrome. Antiviral Res., 2012, vol. 95, no. 3, pp. 282–292. doi: 10.1016/j.antiviral.2012.06.002
  11. Xu W., He J., Wu G., Xiong F., Du H., Wang G. Stabilization and immune response of HBsAg encapsulated within poly(lactic-co-glycolic acid) microspheres using HSA as a stabilizer. Int. J. Pharm., 2015, vol. 496, no. 2, pp. 332–341. doi: 10.1016/j.ijpharm.2015.10.004

补充文件

附件文件
动作
1. JATS XML

版权所有 © Vetrova A.N., Kurashova S.S., Teodorovich R.D., Popova Y.V., Blinova E.A., Nabatnikov P.A., Tkachenko E.А., Dzagurova T.K., 2023

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##